Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:2243-2247
© 2000 American Heart Association, Inc.
Atherosclerosis and Lipoproteins |
Circulating Oxidized Low Density Lipoprotein Levels
A Biochemical Risk Marker for Coronary Heart Disease
From the Second Department of Internal Medicine, Gunma University School of Medicine (S.T., A.H., M.K.), the Department of Internal Medicine, Saiseikai Maebashi Hospital (S.T.), and the Department of Internal Medicine, Gunma Chuoh General Hospital (J.S.), Maebashi, Gunma, Japan; the Department of Microbiology and Molecular Pathology, Faculty of Pharmaceutical Sciences, Teikyo University, Sagamiko (H.I., T.T.), Vessel Research Laboratory Co, Ltd (K.S., J.K.), and the Department of Internal Medicine, Yokohama Sakae Kyosai Hospital (I.M.), Kanagawa, Japan; and the Department of Cardiovascular Medicine, Graduate School of Medicine, University of Tokyo (T.S., R.N.), Tokyo, Japan.
Correspondence to Ryozo Nagai, MD, Department of Cardiovascular Medicine, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. E-mail nagai-tky{at}umin.ac.jp
Abstract—Recent studies have established oxidative modification of low density lipoprotein (LDL) as an important atherogenic factor. We examined the clinical relevance of circulating oxidized LDL (OxLDL) levels in atherosclerotic disease by an enzyme immunoassay with use of specific antibodies against OxLDL (FOH1a/DLH3) and apolipoprotein B. Plasma OxLDL levels were significantly higher in patients with coronary heart disease (n=65) than in control subjects (n=181; 201.3±11.2 versus 112.4±3.3 U/dL, respectively; P<0.01). OxLDL levels were not associated with age, sex, total cholesterol, or apolipoprotein B levels in normal control subjects. Our results suggest that circulating OxLDL may be a possible biochemical risk marker for coronary heart disease.
Key Words: oxidized low density lipoprotein • coronary heart disease • risk factors
This article has been cited by other articles:
 |
|
 |
|
  B. Guldiken, S. Guldiken, B. Turgut, N. Turgut, M. Demir, Y. Celik, E. Arikan, and A. Tugrul The Roles of Oxidized Low-Density Lipoprotein and Interleukin-6 Levels in Acute Atherothrombotic and Lacunar Ischemic Stroke Angiology, May 1, 2008; 59(2): 224 - 229. [Abstract] [PDF]
|
|
|
|
 |
|
 M. Grau, M. Guxens, I. Subirana, M. Fito, M.-I. Covas, B. Jacquemin, J. Sunyer, T. Lanki, S. Picciotto, T. Bellander, et al. South-to-North gradient in lipid peroxidation in men with stable coronary artery disease in Europe Eur. Heart J., December 1, 2007; 28(23): 2841 - 2849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. G. Spagnoli, E. Bonanno, G. Sangiorgi, and A. Mauriello Role of Inflammation in Atherosclerosis J. Nucl. Med., November 1, 2007; 48(11): 1800 - 1815. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Musaad and E. N. Haynes Biomarkers of Obesity and Subsequent Cardiovascular Events Epidemiol. Rev., May 10, 2007; (2007) mxm005v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Koenig and N. Khuseyinova Biomarkers of Atherosclerotic Plaque Instability and Rupture Arterioscler. Thromb. Vasc. Biol., January 1, 2007; 27(1): 15 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. J. Dzau, E. M. Antman, H. R. Black, D. L. Hayes, J. E. Manson, J. Plutzky, J. J. Popma, and W. Stevenson The Cardiovascular Disease Continuum Validated: Clinical Evidence of Improved Patient Outcomes: Part II: Clinical Trial Evidence (Acute Coronary Syndromes Through Renal Disease) and Future Directions Circulation, December 19, 2006; 114(25): 2871 - 2891. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Wu, W. C. Willett, N. Rifai, I. Shai, J. E. Manson, and E. B. Rimm Is Plasma Oxidized Low-Density Lipoprotein, Measured With the Widely Used Antibody 4E6, an Independent Predictor of Coronary Heart Disease Among U.S. Men and Women? J. Am. Coll. Cardiol., September 5, 2006; 48(5): 973 - 979. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-I. Covas, K. Nyyssonen, H. E. Poulsen, J. Kaikkonen, H.-J. F. Zunft, H. Kiesewetter, A. Gaddi, R. de la Torre, J. Mursu, H. Baumler, et al. The effect of polyphenols in olive oil on heart disease risk factors: a randomized trial. Ann Intern Med, September 5, 2006; 145(5): 333 - 341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Tsimikas, J. T. Willerson, and P. M. Ridker C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J. Am. Coll. Cardiol., April 18, 2006; 47(8 Suppl): C19 - C31. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Holvoet, E. Macy, M. Landeloos, D. Jones, J. S. Nancy, F. Van de Werf, and R. P. Tracy Analytical Performance and Diagnostic Accuracy of Immunometric Assays for the Measurement of Circulating Oxidized LDL Clin. Chem., April 1, 2006; 52(4): 760 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Weinbrenner, H. Schroder, V. Escurriol, M. Fito, R. Elosua, J. Vila, J. Marrugat, and M.-I. Covas Circulating oxidized LDL is associated with increased waist circumference independent of body mass index in men and women Am. J. Clinical Nutrition, January 1, 2006; 83(1): 30 - 35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E Toubi and Y Shoenfeld Predictive and protective autoimmunity in cardiovascular diseases: is vaccination therapy a reality? Lupus, September 1, 2005; 14(9): 665 - 669. [Abstract] [PDF]
|
|
|
|
|
|
C. Meisinger, J. Baumert, N. Khuseyinova, H. Loewel, and W. Koenig Plasma Oxidized Low-Density Lipoprotein, a Strong Predictor for Acute Coronary Heart Disease Events in Apparently Healthy, Middle-Aged Men From the General Population Circulation, August 2, 2005; 112(5): 651 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Tsimikas, E. S. Brilakis, E. R. Miller, J. P. McConnell, R. J. Lennon, K. S. Kornman, J. L. Witztum, and P. B. Berger Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease N. Engl. J. Med., July 7, 2005; 353(1): 46 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. Stuveling, S. J. L. Bakker, H. L. Hillege, P. E. de Jong, R. O. B. Gans, and D. de Zeeuw Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol. Dial. Transplant., March 1, 2005; 20(3): 497 - 508. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Virella, M. B. Derrick, V. Pate, C. Chassereau, S. R. Thorpe, and M. F. Lopes-Virella Development of Capture Assays for Different Modifications of Human Low-Density Lipoprotein Clin. Vaccine Immunol., January 1, 2005; 12(1): 68 - 75. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Negishi, H. Shimizu, S. Okada, A. Kuwabara, F. Okajima, and M. Mori 9HODE Stimulates Cell Proliferation and Extracellular Matrix Synthesis in Human Mesangial Cells via PPAR{gamma} Experimental Biology and Medicine, November 1, 2004; 229(10): 1053 - 1060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Shoenfeld, R. Wu, L. D. Dearing, and E. Matsuura Are Anti-Oxidized Low-Density Lipoprotein Antibodies Pathogenic or Protective? Circulation, October 26, 2004; 110(17): 2552 - 2558. [Full Text] [PDF]
|
|
|
|
 |
|
 J.E. Sharman, J.R. Cockcroft, and J.S. Coombes Cardiovascular implications of exposure to traffic air pollution during exercise QJM, October 1, 2004; 97(10): 637 - 643. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Carmena, P. Duriez, and J.-C. Fruchart Atherogenic Lipoprotein Particles in Atherosclerosis Circulation, June 15, 2004; 109(23_suppl_1): III-2 - III-7. [Abstract] [Full Text]
|
|
|
|
|
|
R. Paoletti, A. M. Gotto Jr, and D. P. Hajjar Inflammation in Atherosclerosis and Implications for Therapy Circulation, June 15, 2004; 109(23_suppl_1): III-20 - III-26. [Abstract] [Full Text]
|
|
|
|
 |
|
 P. Holvoet, S. B. Kritchevsky, R. P. Tracy, A. Mertens, S. M. Rubin, J. Butler, B. Goodpaster, and T. B. Harris The Metabolic Syndrome, Circulating Oxidized LDL, and Risk of Myocardial Infarction in Well-Functioning Elderly People in the Health, Aging, and Body Composition Cohort Diabetes, April 1, 2004; 53(4): 1068 - 1073. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S Dhamrait, J. W Stephens, J. A Cooper, J. Acharya, A. R Mani, K. Moore, G. J Miller, S. E Humphries, S. J Hurel, and H. E Montgomery Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2 Eur. Heart J., March 2, 2004; 25(6): 468 - 475. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Shimada, H. Mokuno, E. Matsunaga, T. Miyazaki, K. Sumiyoshi, A. Kume, K. Miyauchi, and H. Daida Predictive Value of Circulating Oxidized LDL for Cardiac Events in Type 2 Diabetic Patients With Coronary Artery Disease Diabetes Care, March 1, 2004; 27(3): 843 - 844. [Full Text] [PDF]
|
|
|
|
|
|
P. Holvoet, T. B. Harris, R. P. Tracy, P. Verhamme, A. B. Newman, S. M. Rubin, E. M. Simonsick, L. H. Colbert, and S. B. Kritchevsky Association of High Coronary Heart Disease Risk Status With Circulating Oxidized LDL in the Well-Functioning Elderly: Findings From the Health, Aging, and Body Composition Study Arterioscler. Thromb. Vasc. Biol., August 1, 2003; 23(8): 1444 - 1448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Uno, K T Kitazato, K Nishi, H Itabe, and S Nagahiro Raised plasma oxidised LDL in acute cerebral infarction J. Neurol. Neurosurg. Psychiatry, March 1, 2003; 74(3): 312 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Bayes, M. C. Pastor, J. Bonal, J. Junca, J. M. Hernandez, N. Riutort, A. Foraster, and R. Romero Homocysteine, C-reactive protein, lipid peroxidation and mortality in haemodialysis patients Nephrol. Dial. Transplant., January 1, 2003; 18(1): 106 - 112. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kopprasch, J. Pietzsch, E. Kuhlisch, K. Fuecker, T. Temelkova-Kurktschiev, M. Hanefeld, H. Kuhne, U. Julius, and J. Graessler In Vivo Evidence for Increased Oxidation of Circulating LDL in Impaired Glucose Tolerance Diabetes, October 1, 2002; 51(10): 3102 - 3106. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Nishi, H. Itabe, M. Uno, K. T. Kitazato, H. Horiguchi, K. Shinno, and S. Nagahiro Oxidized LDL in Carotid Plaques and Plasma Associates With Plaque Instability Arterioscler. Thromb. Vasc. Biol., October 1, 2002; 22(10): 1649 - 1654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Hulthe and B. Fagerberg Circulating Oxidized LDL Is Associated With Subclinical Atherosclerosis Development and Inflammatory Cytokines (AIR Study) Arterioscler. Thromb. Vasc. Biol., July 1, 2002; 22(7): 1162 - 1167. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tanaga, H. Bujo, M. Inoue, K. Mikami, K. Kotani, K. Takahashi, T. Kanno, and Y. Saito Increased Circulating Malondialdehyde-Modified LDL Levels in Patients With Coronary Artery Diseases and Their Association With Peak Sizes of LDL Particles Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 662 - 666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Bach Heterogeneity of response to lipid-lowering therapy J. Am. Coll. Cardiol., December 1, 2001; 38(7): 2136 - 2137. [Full Text] [PDF]
|
|
|
|
 |
|
 A. MERTENS and P. HOLVOET Oxidized LDL and HDL: antagonists in atherothrombosis FASEB J, October 1, 2001; 15(12): 2073 - 2084. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tanaga, H. Bujo, M. Inoue, K. Mikami, K. Kotani, K. Takahashi, T. Kanno, and Y. Saito Increased Circulating Malondialdehyde-Modified LDL Levels in Patients With Coronary Artery Diseases and Their Association With Peak Sizes of LDL Particles Arterioscler. Thromb. Vasc. Biol., April 1, 2002; 22(4): 662 - 666. [Abstract] [Full Text] [PDF]
|
|